Payment overview · 2025
General Payments
$151.07
5 reported records · 4 companies
Healthcare provider profile · identity verified
Sanjeev Bhatia, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · VICTORIA, TX · NPI 1275513491
Verified facts
What the public records show
CMS Open Payments records show Sanjeev Bhatia, M.D. received $151.07 in general payments during 2025 across 5 reported records.
Madrigal Pharmaceuticals accounted for 51.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $77.04 | 51.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $31.22 | 20.7% | 2 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $27.60 | 18.3% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$15.21 | 10.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $151.07 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $77.04 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $31.22 | 2 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $27.60 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $27.60 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $15.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 440 | 188 |
| Amlodipine Besylate | Amlodipine Besylate | 393 | 146 |
| Levothyroxine Sodium | Levothyroxine Sodium | 326 | 107 |
| Lisinopril | Lisinopril | 314 | 131 |
| Gabapentin | Gabapentin | 239 | 98 |
| Metoprolol Succinate | Metoprolol Succinate | 224 | 74 |
| Metformin Hcl | Metformin Hcl | 210 | 80 |
| Pantoprazole Sodium | Pantoprazole Sodium | 182 | 76 |
| Furosemide | Furosemide | 172 | 76 |
| Losartan Potassium | Losartan Potassium | 150 | 55 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 143 | 70 |
| Pravastatin Sodium | Pravastatin Sodium | 141 | 65 |
| Metoprolol Tartrate | Metoprolol Tartrate | 137 | 58 |
| Omeprazole | Omeprazole | 130 | 47 |
| Prednisone | Prednisone | 125 | 83 |
| Famotidine | Famotidine | 124 | 58 |
| Montelukast Sodium | Montelukast Sodium | 101 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 101 | 46 |
| Simvastatin | Simvastatin | 101 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 100 | 38 |
| Azithromycin | Azithromycin | 99 | 79 |
| Potassium Chloride | Potassium Chloride | 94 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 93 | 41 |
| Naproxen | Naproxen | 90 | 50 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 89 | 58 |
| Ozempic | Semaglutide | 86 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 84 | 35 |
| Glipizide | Glipizide | 82 | 30 |
| Jardiance | Empagliflozin | 82 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 80 | 34 |
| Eliquis | Apixaban | 78 | 24 |
| Sertraline Hcl | Sertraline Hcl | 78 | 33 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 20 |
| Carvedilol | Carvedilol | 64 | 26 |
| Clonidine Hcl | Clonidine Hcl | 64 | 28 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 61 | 36 |
| Cephalexin | Cephalexin | 58 | 49 |
| Fenofibrate | Fenofibrate Nanocrystallized | 58 | 23 |
| Meloxicam | Meloxicam | 56 | 34 |
| Mounjaro | Tirzepatide | 56 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 22 |
| Allopurinol | Allopurinol | 50 | 14 |
| Glimepiride | Glimepiride | 49 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 48 | 44 |
| Hydralazine Hcl | Hydralazine Hcl | 46 | 22 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 46 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 43 | 37 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 30 |
| Methylprednisolone | Methylprednisolone | 42 | 35 |
| Symbicort | Budesonide/Formoterol Fumarate | 42 | 15 |
| Trazodone Hcl | Trazodone Hcl | 41 | 15 |
| Cefuroxime | Cefuroxime Axetil | 40 | 37 |
| Ezetimibe | Ezetimibe | 39 | 14 |
| Ondansetron Odt | Ondansetron | 38 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 29 |
| Cefdinir | Cefdinir | 35 | 33 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 30 | 13 |
| Folic Acid | Folic Acid | 30 | 14 |
| Donepezil Hcl | Donepezil Hcl | 29 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | 12 |
| Celecoxib | Celecoxib | 28 | suppressed |
| Fluconazole | Fluconazole | 27 | 23 |
| Lagevrio (Eua) | Molnupiravir | 27 | 27 |
| Trulicity | Dulaglutide | 27 | suppressed |
| Sodium Polystyrene Sulfonate | Sodium Polystyrene Sulfonate | 26 | 23 |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 21 |
| Nitroglycerin | Nitroglycerin | 25 | 22 |
| Spironolactone | Spironolactone | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 23 |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 22 |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 23 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 15 |
| Ibuprofen | Ibuprofen | 19 | 13 |
| Meclizine Hcl | Meclizine Hcl | 19 | 14 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 19 | 18 |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Glipizide Er | Glipizide | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 16 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Atenolol | Atenolol | 15 | suppressed |
| Colchicine | Colchicine | 15 | 11 |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Constulose | Lactulose | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Nystatin | Nystatin | 13 | 11 |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Incontrol Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $151.07 · 5 records | Madrigal Pharmaceuticals | Flexitouch Plus, INCEPTIV, Kerendia, Nimbl, REZDIFFRA | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error